Skip to main content
SpringerLink
Log in
Book cover

Neuroendocrine Tumours pp 475–489Cite as

Liver-Directed Therapies in Neuroendocrine Tumors

  • Chapter

  • 1625 Accesses

Abstract

Presence of liver metastases in neuroendocrine tumors is a major factor altering both quality of life and prognosis. Surgery is recognized as the sole curative treatment. When it is not possible, radiological-directed therapies are crucial.

This chapter addresses the various roles, technical issues, clinical efficacy, and safety of thermal ablation (radiofrequency, microwave, and cryotherapy) and transarterial embolization (bland embolization, chemoembolization, and radioembolization) as liver-directed therapies.

The choice of management depends on liver burden and metastases pattern but also on origin of the primary tumor, tumor differentiation, and tumor proliferative activity.

The treatment of neuroendocrine liver metastases still needs to be standardized. Management in centers of expertise should be strongly encouraged in order to enable a multidisciplinary approach to limit morbidity and mortality.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plockinger U (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12(6):361–379. doi:10.1111/j.1477-2574.2010.00175.x, HPB175 [pii]

    Article  Google Scholar 

  2. Godwin JD 2nd (1975) Carcinoid tumors. An analysis of 2,837 cases. Cancer 36(2):560–569

    Article  PubMed  Google Scholar 

  3. McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81(7):1007–1009

    Article  CAS  PubMed  Google Scholar 

  4. Zeitels J, Naunheim K, Kaplan EL, Straus F 2nd (1982) Carcinoid tumors: a 37-year experience. Arch Surg 117(5):732–737

    Article  CAS  PubMed  Google Scholar 

  5. Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60(7):1009–1021. doi:10.1136/gut.2009.204453, gut.2009.204453 [pii]

    Article  CAS  PubMed  Google Scholar 

  6. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Levy P, Vilgrain V, Ruszniewski P, Belghiti J (2008) Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247(4):659–665. doi:10.1097/SLA.0b013e31816a7061

    Article  PubMed  Google Scholar 

  7. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C, Baudin E (2003) Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133(4):375–382. doi:10.1067/msy.2003.114, S0039606003000096 [pii]

    Article  PubMed  Google Scholar 

  8. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445, doi:S1072-7515(00)00222-2 [pii]

    Article  CAS  PubMed  Google Scholar 

  9. Elias D, Goere D, Leroux G, Dromain C, Leboulleux S, de Baere T, Ducreux M, Baudin E (2009) Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 35(10):1092–1097. doi:10.1016/j.ejso.2009.02.017, S0748-7983(09)00077-8 [pii]

    Article  CAS  PubMed  Google Scholar 

  10. Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E (2010) Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 148(6):1288–1293. doi:10.1016/j.surg.2010.09.014; discussion 1293. S0039-6060(10)00506-4 [pii]

    Article  PubMed  Google Scholar 

  11. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242(2):158–171, doi:00000658-200508000-00003 [pii]

    Article  PubMed Central  PubMed  Google Scholar 

  12. Berber E, Siperstein AE (2007) Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc 21(4):613–618. doi:10.1007/s00464-006-9139-y

    Article  CAS  PubMed  Google Scholar 

  13. Mazzaglia PJ, Berber E, Milas M, Siperstein AE (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142(1):10–19. doi:10.1016/j.surg.2007.01.036, S0039-6060(07)00201-2 [pii]

    Article  PubMed  Google Scholar 

  14. Martin RC, Scoggins CR, McMasters KM (2010) Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 17(1):171–178. doi:10.1245/s10434-009-0686-z

    Article  PubMed  Google Scholar 

  15. Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP (1997) Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122(6):1040–1047; discussion 1047–1048. doi:S0039-6060(97)90207-5 [pii]

    Article  CAS  PubMed  Google Scholar 

  16. Seifert JK, Cozzi PJ, Morris DL (1998) Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14(2):175–183, doi:10.1002/(SICI)1098-2388(199803)14:2<175::AID-SSU10>3.0.CO;2-2 [pii]

    Article  CAS  PubMed  Google Scholar 

  17. Shapiro RS, Shafir M, Sung M, Warner R, Glajchen N (1998) Cryotherapy of metastatic carcinoid tumors. Abdom Imaging 23(3):314–317

    Article  CAS  PubMed  Google Scholar 

  18. Steward MJ, Warbey VS, Malhotra A, Caplin ME, Buscombe JR, Yu D (2008) Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics 28(4):1131–1145. doi:10.1148/rg.284075170, 28/4/1131 [pii]

    Article  PubMed  Google Scholar 

  19. Granberg D, Eriksson LG, Welin S, Kindmark H, Janson ET, Skogseid B, Oberg K, Eriksson B, Nyman R (2007) Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors. Acta Radiol 48(2):180–185. doi:10.1080/02841850601080440, 772611718 [pii]

    Article  CAS  PubMed  Google Scholar 

  20. Therasse E, Breittmayer F, Roche A, De Baere T, Indushekar S, Ducreux M, Lasser P, Elias D, Rougier P (1993) Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 189(2):541–547

    Article  CAS  PubMed  Google Scholar 

  21. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S (1986) The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147(1):149–154

    Article  CAS  PubMed  Google Scholar 

  22. Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors–a retrospective single-center analysis. Digestion 68(2–3):94–101. doi:10.1159/000074522, 74522 [pii]

    Article  CAS  PubMed  Google Scholar 

  23. Eriksson BK, Larsson EG, Skogseid BM et al (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83(11):2293–2301, doi:10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E [pii]

    Article  CAS  PubMed  Google Scholar 

  24. Kim YH, Ajani JA, Carrasco CH et al (1999) Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 17(7):474–478

    Article  CAS  PubMed  Google Scholar 

  25. Marrache F, Vullierme MP, Roy C et al (2007) Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 96(1):49–55. doi:10.1038/sj.bjc.6603526, 6603526 [pii]

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Roche A, Girish BV, de Baere T et al (2004) Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 51(60):1751–1756

    CAS  PubMed  Google Scholar 

  27. Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590–1602. doi:10.1002/cncr.21389

    Article  PubMed  Google Scholar 

  28. Ruszniewski P, Rougier P, Roche A et al (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71(8):2624–2630

    Article  CAS  PubMed  Google Scholar 

  29. Maire F, Lombard-Bohas C, O’Toole D et al (2012) Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases of well-differentiated midgut endocrine tumors. A prospective randomized study. Neuroendocrinology 96:294–300

    Article  CAS  PubMed  Google Scholar 

  30. Pitt SC, Knuth J, Keily JM et al (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12(11):1951–1960. doi:10.1007/s11605-008-0640-6

    Article  PubMed Central  PubMed  Google Scholar 

  31. Ruutiainen AT, Soulen MC, Tuite CM et al (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18(7):847–855. doi:10.1016/j.jvir.2007.04.018, 18/7/847 [pii]

    Article  PubMed  Google Scholar 

  32. Fiore F, Del Prete M, Franco R et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47:177–182. doi:10.1007/s12020-013-0130-9

    Article  CAS  PubMed  Google Scholar 

  33. Strosberg JR, Weber JM, Choi J et al (2012) A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 23(9):2335–2341. doi:10.1093/annonc/mdr614, mdr614 [pii]

    Article  CAS  PubMed  Google Scholar 

  34. Dominguez S, Denys A, Madeira I et al (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12(2):151–157

    Article  CAS  PubMed  Google Scholar 

  35. Ho AS, Picus J, Darcy MD et al (2007) Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188(5):1201–1207. doi:10.2214/AJR.06.0933, 188/5/1201 [pii]

    Article  PubMed  Google Scholar 

  36. Strosberg JR, Choi J, Cantor AB, Kvols LK (2006) Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13(1):72–78

    PubMed  Google Scholar 

  37. Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52. doi:10.1007/s00270-009-9711-7

    Article  PubMed Central  PubMed  Google Scholar 

  38. de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, Leboulleux S, Baudin E, Hechellhammer L (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19(6):855–861. doi:10.1016/j.jvir.2008.01.030, S1051-0443(08)00183-8 [pii]

    Article  PubMed  Google Scholar 

  39. Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, Kulke M, Baum R (2011) Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 34(3):566–572. doi:10.1007/s00270-011-0122-1

    Article  PubMed  Google Scholar 

  40. Guiu B, Deschamps F, Aho S et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56(3):609–617. doi:10.1016/j.jhep.2011.09.012, S0168-8278(11)00773-2 [pii]

    Article  CAS  PubMed  Google Scholar 

  41. Bhagat N, Reyes DK, Lin M et al (2013) Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 36(2):449–459. doi:10.1007/s00270-012-0424-y

    Article  PubMed Central  PubMed  Google Scholar 

  42. Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A (2012) Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 17(5):725–731. doi:10.1634/theoncologist.2011-0372, theoncologist.2011-0372 [pii]

    Article  PubMed Central  PubMed  Google Scholar 

  43. Hoffmann RT, Paprottka P, Jakobs TF, Trumm CG, Reiser MF (2011) Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Abdom Imaging 36(6):671–676. doi:10.1007/s00261-011-9753-6

    Article  PubMed  Google Scholar 

  44. Varker KA, Martin EW, Klemanski D, Palmer B, Shah MH, Bloomston M (2007) Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE. J Gastrointest Surg 11(12):1680–1685. doi:10.1007/s11605-007-0235-7

    Article  PubMed  Google Scholar 

  45. Kim W, Clark TW, Baum RA, Soulen MC (2001) Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12(8):965–968

    Article  CAS  PubMed  Google Scholar 

  46. de Baere T, Roche A, Amenabar JM, Lagrange C, Ducreux M, Rougier P, Elias D, Lasser P, Patriarche C (1996) Liver abscess formation after local treatment of liver tumors. Hepatology 23(6):1436–1440. doi:10.1002/hep.510230620, S0270913996002315 [pii]

    Article  PubMed  Google Scholar 

  47. Woo S, Chung JW, Hur S, Joo SM, Kim HC, Jae HJ, Park JH (2013) Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol 200(6):1370–1377. doi:10.2214/AJR.12.9630

    Article  PubMed  Google Scholar 

  48. Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH (1999) Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10(4):397–403

    Article  CAS  PubMed  Google Scholar 

  49. Sommer WH, Ceelen F, Garcia-Albeniz X et al (2013) Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol 23(11):3094–3103. doi:10.1007/s00330-013-2925-8

    Article  PubMed  Google Scholar 

  50. Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31(3):271–279. doi:10.1097/COC.0b013e31815e4557, 00000421-200806000-00012 [pii]

    Article  PubMed  Google Scholar 

  51. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97(4):537–543. doi:10.1002/bjs.6931

    Article  CAS  PubMed  Google Scholar 

  52. Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H, Gress TM, Arnold R, Klose KJ, Wagner HJ (2009) Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79(3):137–142. doi:10.1159/000209849, 000209849 [pii]

    Article  PubMed  Google Scholar 

  53. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113(5):921–929. doi:10.1002/cncr.23685

    Article  PubMed  Google Scholar 

  54. Paprottka PM, Hoffmann RT, Haug A et al (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35(2):334–342. doi:10.1007/s00270-011-0248-1

    Article  PubMed  Google Scholar 

  55. Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, Benson AB 3rd, Kennedy AS, Omary RA, Salem R (2008) 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247(6):1029–1035. doi:10.1097/SLA.0b013e3181728a45, 00000658-200806000-00017 [pii]

    Article  PubMed  Google Scholar 

  56. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251(5):910–916. doi:10.1097/SLA.0b013e3181d3d24a

    Article  PubMed  Google Scholar 

  57. Ceelen F, Theisen D, de Albeniz XG et al (2014) Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? J Magn Reson Imaging. doi:10.1002/jmri.24569

  58. Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Gates VL, Atassi B, Newman S, Omary RA, Benson AB 3rd, Salem R (2012) Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 83(3):887–894. doi:10.1016/j.ijrobp.2011.07.041, S0360-3016(11)03133-6 [pii]

    Article  PubMed Central  PubMed  Google Scholar 

  59. Rajekar H, Bogammana K, Stubbs RS (2011) Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int J Hepatol 2011:404916. doi:10.4061/2011/404916

    PubMed Central  PubMed  Google Scholar 

  60. Benson AB 3rd, Geschwind JF, Mulcahy MF et al (2013) Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 49(15):3122–3130. doi:10.1016/j.ejca.2013.05.012, S0959-8049(13)00409-7 [pii]

    Article  PubMed  Google Scholar 

  61. Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O’Dorisio TM, Howe J, Button A, Zamba G, Halfdanarson TR (2014) Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas 43(2):219–225. doi:10.1097/MPA.0000000000000030, 00006676-201403000-00007 [pii]

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Whitney R, Valek V, Fages JF, Garcia A, Narayanan G, Tatum C, Hahl M, Martin RC 2nd (2011) Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist 16(5):594–601. doi:10.1634/theoncologist.2010-0292, theoncologist.2010-0292 [pii]

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Yang TX, Chua TC, Morris DL (2012) Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – a systematic review. Surg Oncol 21(4):299–308. doi:10.1016/j.suronc.2012.07.001, S0960-7404(12)00054-0 [pii]

    Article  PubMed  Google Scholar 

  64. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176. doi:10.1159/000335597, 000335597 [pii]

    Article  CAS  PubMed  Google Scholar 

  65. Cadiot G (2010) Tumeurs endocrines digestives. Thésaurus National de cancérologie Digestive. Available via http://www.snfge.org/data/moduledocument/publication/5/1252.htm

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, 100, boulevard du Général Leclerc, 92110, Clichy, France

    Magaly Zappa, Annie Sibert, Mohamed Abdel-Rehim, Maxime Ronot, Marie-Pierre Vullierme & Valérie Vilgrain

  2. Univ Paris Diderot, Sorbonne, Paris Cité, CRB3 Inserm U773, 75018, Paris, France

    Magaly Zappa, Maxime Ronot, Valérie Vilgrain & Philippe Ruszniewski

  3. Department of Gastroenterology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, 100, boulevard du Général Leclerc, 92110, Clichy, France

    Olivia Hentic & Philippe Ruszniewski

Authors
  1. Magaly Zappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annie Sibert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Abdel-Rehim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olivia Hentic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maxime Ronot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marie-Pierre Vullierme
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valérie Vilgrain
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Philippe Ruszniewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Magaly Zappa .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Suayib Yalcin

  2. Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

    Kjell Öberg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Zappa, M. et al. (2015). Liver-Directed Therapies in Neuroendocrine Tumors. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45215-8_26

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45214-1

  • Online ISBN: 978-3-662-45215-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation